|
KMID : 0378019930360030065
|
|
New Medical Journal
1993 Volume.36 No. 3 p.65 ~ p.71
|
|
|
A Preliminary Study of Immunogenecity and Safety of Inactivated Hemorrhagic Fever with Renal Syndrome Vaccine (Hantavax) in Children
|
|
|
|
|
Abstract
|
|
|
The immunogenicity and safety of purified inactivated HFRS vaccine from suckling rat brain was evaluated in 102 children. The vaccination was carried out two times with interval of I month in two groups. 0.25ml per dose (4096 ELISA unit of vaccine/0.5m1) was administered subcutaneously to group I (5-12 years, 46cases) and 0.5ml per dose was administered subcutaneously to group II (11-18 years, 56cases).
The results were as follows
1. Seroconversion rates of IgG in group I and 11 were 97.8% (45/46), 92.99/0 (52/56) after primary vaccination and 92.9%0 (52/56), 96.4% (54/56) after secondary vaccination respectively.
2. Titers of IgG antibody in group I and II were 1 :320.70±345.98, 1:211.71±213.42 after. primary vaccination and 1 :876.87±978.22, 1 :468.57±434.60 after secondary vaccination respectively. Group I showed higher titer of IgG antibody than group II after vaccination.
3. Difference of seroconversion rate and titer of IgG antibody by vaccine dose in same aged group was not significant.
4. No significant adverse reactions were observed except mild fever and swelling on injection site in both group.
As a result, the HFRS vaccine is considered to be safe and to have good immunogenicity for the prevention of HFRS in children. But further study on the persistence of immunogenecity and the time of booster vaccination should be determined.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|